Literature DB >> 26914914

Cutaneous Adverse Effects of Neurologic Medications.

Eman Bahrani1, Chloe E Nunneley1, Sylvia Hsu2, Joseph S Kass3.   

Abstract

Life-threatening and benign drug reactions occur frequently in the skin, affecting 8 % of the general population and 2-3 % of all hospitalized patients, emphasizing the need for physicians to effectively recognize and manage patients with drug-induced eruptions. Neurologic medications represent a vast array of drug classes with cutaneous side effects. Approximately 7 % of the United States (US) adult population is affected by adult-onset neurological disorders, reflecting a large number of patients on neurologic drug therapies. This review elucidates the cutaneous reactions associated with medications approved by the US Food and Drug Administration (FDA) to treat the following neurologic pathologies: Alzheimer disease, amyotrophic lateral sclerosis, epilepsy, Huntington disease, migraine, multiple sclerosis, Parkinson disease, and pseudobulbar affect. A search of the literature was performed using the specific FDA-approved drug or drug classes in combination with the terms 'dermatologic,' 'cutaneous,' 'skin,' or 'rash.' Both PubMed and the Cochrane Database of Systematic Reviews were utilized, with side effects ranging from those cited in randomized controlled trials to case reports. It behooves neurologists, dermatologists, and primary care physicians to be aware of the recorded cutaneous adverse reactions and their severity for proper management and potential need to withdraw the offending medication.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26914914     DOI: 10.1007/s40263-016-0318-7

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   6.497


  257 in total

1.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors: 
Journal:  Arch Neurol       Date:  2002-12

2.  Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.

Authors:  B Kocer; B Nazliel; M Oztas; H Z Batur
Journal:  Eur J Neurol       Date:  2009-04       Impact factor: 6.089

Review 3.  Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy.

Authors:  Maja Mockenhaupt
Journal:  J Dtsch Dermatol Ges       Date:  2009-02       Impact factor: 5.584

4.  Two cases of herpes zoster appearing after botulinum toxin type a injections.

Authors:  Emmy M Graber; Jeffrey S Dover; Kenneth A Arndt
Journal:  J Clin Aesthet Dermatol       Date:  2011-10

5.  Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b.

Authors:  W A Sheremata; J R Taylor; G W Elgart
Journal:  N Engl J Med       Date:  1995-06-08       Impact factor: 91.245

6.  Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.

Authors:  D Chadwick
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

Review 7.  Antiepileptic drug hypersensitivity syndrome.

Authors:  R G Schlienger; N H Shear
Journal:  Epilepsia       Date:  1998       Impact factor: 5.864

8.  Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6.

Authors:  Yuichi Teraki; Haruhiko Murota; Seiichi Izaki
Journal:  Arch Dermatol       Date:  2008-02

9.  Palmar erythema due to topiramate.

Authors:  Noah Scheinfeld; Candice Spahn
Journal:  J Drugs Dermatol       Date:  2004 May-Jun       Impact factor: 2.114

10.  Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.

Authors:  Nigel J Ball; Bryce J Cowan; G R Wayne Moore; Stanley A Hashimoto
Journal:  J Cutan Pathol       Date:  2008-04       Impact factor: 1.587

View more
  1 in total

1.  An inventory of medicinal products causing skin rash: Clinical and regulatory lessons.

Authors:  Robert Ancuceanu; Mihaela Dinu; Florentina Furtunescu; Daniel Boda
Journal:  Exp Ther Med       Date:  2019-07-31       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.